ArticleInternational journal of molecular sciences2026
Tumor-Informed ddPCR for Personalized Longitudinal ctDNA Monitoring in Advanced Solid Tumors: Molecular-Radiological Concordance and Molecular Lead Time.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serial circulating tumor DNA (ctDNA) monitoring may complement episodic radiological response assessment during systemic therapy. We evaluated personalized tumor-informed droplet digital PCR (ddPCR) for longitudinal ctDNA monitoring in advanced solid tumors, focusing on RECIST-associated ctDNA levels, anatomical tumor burden, molecular-radiological concordance, molecular lead time (MLT), and routine implementation. The clinical cohort comprised 61 patients with breast, colorectal, gynecological, head and neck, lung, pancreaticobiliary, or other advanced solid tumors and 385 longitudinal patient-specific ddPCR assessments; 357 assessments were imaging-concurrent. Repeated RECIST-stratified measurements were evaluated descriptively and using patient-clustered generalized estimating equations (GEEs). Longitudinal trajectories were classified using study-specific Longitudinal Concordance Level (LCL) and Molecular Evidence Level (MEL) frameworks. A separate real-world implementation cohort comprised 270 patients and 650 personalized ddPCR assays; 88 patients underwent two or more serial assessments. Among the 357 imaging-concurrent assessments, 90 were partial response (PR), 117 stable disease (SD), and 150 progressive disease (PD). Median VAF was 0.055% in PR, 0.190% in SD, and 0.205% in PD. Patient-clustered GEEs confirmed an overall association between VAF and RECIST category (Wald χ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.